Thalidomid/Interleukin-2 in der Second-line-Therapie des metastasierten Nierenzellkarzinoms - Ergebnisse einer Pilotstudie

Abstract

We conclude that outpatient administration of thalidomide/IL-2 is feasible in patients with heavily pretreated and progressive RCC who desire further active treatment. However, toxicity and costs are considerable and the clinical benefit is uncertain. Therefore thalidomide/IL-2 may not represent a promising therapeutic approach for this subgroup of patients.

Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide

“…In comparison to the studies of Hofmockel et al [1], where IL-2, IFN-alpha and 5-FU had been given and the thalidomide/IL-2 therapy by Schrader et al [7], the treatment of this phase I study consisted of thalidomide in combination with 5-FU.…”